ERBB2 and neoplasm: CUDC-101 is a potent HDAC inhibitor that synergistically inhibits EGFR/HER2 kinases and attenuates multiple compensatory pathways, such as AKT; it also suppresses the progression of a broad range of tumor types in both in vitro and in vivo xenograft models [97].